These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 18259011)

  • 21. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Wachtell K; Dahlöf B; Rokkedal J; Papademetriou V; Nieminen MS; Smith G; Gerdts E; Boman K; Bella JN; Devereux RB
    Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.
    Palmieri V; Wachtell K; Gerdts E; Bella JN; Papademetriou V; Tuxen C; Nieminen MS; Dahlöf B; de Simone G; Devereux RB
    Am Heart J; 2001 May; 141(5):784-91. PubMed ID: 11320367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy.
    Okin PM; Gerdts E; Kjeldsen SE; Julius S; Edelman JM; Dahlöf B; Devereux RB;
    Hypertension; 2008 Jul; 52(1):100-6. PubMed ID: 18504323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).
    Gerdts E; Cramariuc D; de Simone G; Wachtell K; Dahlöf B; Devereux RB
    Eur J Echocardiogr; 2008 Nov; 9(6):809-15. PubMed ID: 18490279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SILVHIA).
    Liljedahl S; Kahan T; Lind L; Arnlöv J
    Echocardiography; 2009 Aug; 26(7):753-8. PubMed ID: 19486119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of hypertension in patients with left ventricular hypertrophy].
    Omvik P; Bratland B; Gerhardsen G; Gisholt K; Risanger T; Smedsrud T; Kjeldsen SE
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):788-91. PubMed ID: 15039810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy.
    Biederman RW; Doyle M; Young AA; Devereux RB; Kortright E; Perry G; Bella JN; Oparil S; Calhoun D; Pohost GM; Dell'Italia LJ
    Hypertension; 2008 Aug; 52(2):279-86. PubMed ID: 18606908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of regression of left ventricular hypertrophy from systemic hypertension on systolic function assessed by midwall shortening (HOT echocardiographic study).
    Zabalgoitia M; Rahman SN; Haley WE; Yarows S; Krause L; Anderson LC; Oraby MA; Amarena J
    Am J Cardiol; 2001 Sep; 88(5):521-5. PubMed ID: 11524061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
    Wachtell K; Papademetriou V; Smith G; Gerdts E; Dahlöf B; Engblom E; Aurigemma GP; Bella JN; Ibsen H; Rokkedal J; Devereux RB
    Am Heart J; 2004 Sep; 148(3):538-44. PubMed ID: 15389245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors influencing left ventricular structure and stress-corrected systolic function in men and women with asymptomatic aortic valve stenosis (a SEAS Substudy).
    Cramariuc D; Rieck AE; Staal EM; Wachtell K; Eriksen E; Rossebø AB; Gerdts E
    Am J Cardiol; 2008 Feb; 101(4):510-5. PubMed ID: 18312768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
    Okin PM; Wachtell K; Gerdts E; Dahlöf B; Devereux RB
    J Hypertens; 2014 Dec; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy).
    Gerdts E; Björnstad H; Devereux RB; Lund-Jhansen P; Davidsen ES; Omvik P
    Blood Press; 2006; 15(4):220-6. PubMed ID: 17060116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
    Mancusi C; Gerdts E; de Simone G; Midtbø H; Lønnebakken MT; Boman K; Wachtell K; Dahlöf B; Devereux RB
    Blood Press; 2017 Jun; 26(3):150-155. PubMed ID: 27710139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Lindholm LH; Dahlöf B;
    Hypertension; 2007 Nov; 50(5):984-90. PubMed ID: 17893425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Narayan P; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am Heart J; 2009 Jan; 157(1):177-84. PubMed ID: 19081416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
    Boman K; Gerdts E; Wachtell K; Dahlöf B; Nieminen MS; Olofsson M; Papademetriou V; Devereux RB
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):242-8. PubMed ID: 19369828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of overweight and obesity on cardiac benefit of antihypertensive treatment.
    Gerdts E; de Simone G; Lund BP; Okin PM; Wachtell K; Boman K; Nieminen MS; Dahlöf B; Devereux RB
    Nutr Metab Cardiovasc Dis; 2013 Feb; 23(2):122-9. PubMed ID: 21775111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
    Oikarinen L; Nieminen MS; Viitasalo M; Toivonen L; Jern S; Dahlöf B; Devereux RB; Okin PM;
    Hypertension; 2004 May; 43(5):1029-34. PubMed ID: 15037560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.